

PHARMACEUTICAL 2022

Innovation1 Biotech Inc. Rank 434 of 466









PHARMACEUTICAL 2022



Innovation1 Biotech Inc. Rank 434 of 466

The relative strengths and weaknesses of Innovation1 Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innovation1 Biotech Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Innovation1 Biotech Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -213%, being 291% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	168
Cost of Goods Sold	1.4
Intangible Assets	0
Liabilities, Current	407
Liabilities, Non-Current	0
Other Assets	13
Other Compr. Net Income	0
Other Expenses	191
Other Liabilities	0
Other Net Income	0
Other Revenues	3.1
Property and Equipment	0.60
Research and Development	0
Selling, General and Administrative Expense	49

Output Variable	Value in 1000 USD
Assets	182
Liabilities	407
Expenses	242
Revenues	3.1
Stockholders Equity	-225
Net Income	-239
Comprehensive Net Income	-239
Economic Capital Ratio	-213%

